Equity (Details) $ / shares in Units, vaccine_dose in Millions, $ in Millions		1 Months Ended
	Mar. 18, 2021 USD ($) vaccine_dose	Aug. 31, 2024 USD ($) shares	Jul. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 01, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in USD per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Shares authorized (in shares) | shares			400,000,000
Common stock, shares authorized (in shares) | shares			390,000,000	390,000,000	390,000,000
Preferred stock, shares authorized to issue (in shares) | shares			10,000,000	10,000,000	10,000,000
Preferred stock, par value (in USD per share) | $ / shares			$ 0.01	$ 0.01	$ 0.01
Preferred stock, amount issued | $								$ 5.0
Preferred stock, amount outstanding | $						$ 4.1	$ 4.1
Level 3 | Discount Rate
Subsidiary, Sale of Stock [Line Items]
Preferred stock, measurement input							0.15
July 2024 Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares			30,400,000
Common stock, par value (in USD per share) | $ / shares			$ 0.01
Price per share of shares issued in underwriting agreement (in USD per share) | $ / shares			$ 1.15
Proceeds from sale of shares issued in underwriting agreement | $			$ 32.3
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold (in shares) | shares		2,282,608	4,565,217
Option period purchase additional shares in underwriting agreement			30 days
Proceeds from sale of shares issued in underwriting agreement | $		$ 2.4
COVAXIN Preferred Stock Purchase Agreement
Subsidiary, Sale of Stock [Line Items]
Preferred stock, par value (in USD per share) | $ / shares									$ 0.01
Agreement to sell, number of shares issued in transaction (in shares) | shares									100,000
Agreement to sell, price per share (in USD per share) | $ / shares									$ 109.60
Advance payment amount | $	$ 6.0
Conversion ratio (in shares)									10
Supply agreement, number of doses | vaccine_dose	10.0